From product development to translation into clinical trials, GTx’s clinically validated scalable electroporation technology is equipped to handle your most complex cellular engineering demands.

Rapidly transfect from 75 thousand to 20 billion cells

Move forward with 21 CFR Part 11 enabled software

Develop quickly with an established regulatory path supported by a FDA Master File

Manufacture confidently with closed, cGMP-compliant, ISO-certified and CE-marked products

Enjoy MaxCyte’s proprietary Flow Electroporation technology

Product Features

Integrated Touch-Screen - Easily operate with just the touch of a finger.

Enhanced Software User Interface - Save time with regulatory compliant functionality and intuitive ease of use software.

Barcode Reader - Capture important sample processing details and minimize manual information entry.

Network Capable - Generate and save run reports automatically onto a shared local drive.

LED Status Indicators - Quickly visualize instrument and run status with 6 colorful and clearly defined status modes.

Retractable Bag Hooks - Utilize convenient hooks for large volume processing and then fold them away when you don’t need them.

Reduced Footprint - Bench-scale, modular equipment.

Elegant Design - Enjoy a modern, sleek appearance that fits seamlessly into any high-tech lab space.


Choosing MaxCyte® gives you more than just an instrument — partner with an expert in cell engineering with the knowledge to support you during every stage of your journey of discovery.

Supporting Products

Compatible Consumables & Accessories


G-1000 Clinically produce your therapeutic end product in as little as 400 uL and up to 1 mL and from 2x106, to 2x108 cells


  • Enhanced design for improved handling
  • Locking lid to secure sample
  • Well designed for efficient loading and unloading of cells
  • Made of medical grade and inert materials to protect precious cells

Closed Buffer Save time with seamless, sterile buffer exchange for automated cell concentration


  • Closed process compatible
  • 500 mL and 1 L bag options
  • Adaptable to cell concentration and buffer exchange processes
  • Connection flexibility

CL-2 GMP Clinically produce your therapeutic product up to 100 mL working volume with this Flow Electroporation enabled processing assembly


  • Closed system and biowelding compatible
  • Flow Electroporation enables processing of up to 20 billion cells in 30 minutes
  • Made of high grade and inert material to protect previous cells

Px5 Workflow Rack Easily and securely hold, load, manage and transport up to 5 small volume Processing Assemblies


  • Holds 1 to 5 small volume PAs (≤1 ml)
  • “To Do” and “Done” positions for tracking PA workflow status
  • Durable, stackable, low footprint
  • Withstands common lab disinfectants

Find more

Research Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Antibody & Protein Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Learn how scientists are using GTx™


An Alternative Vector Platform for the Manufacture of Recombinant T cells for Autologous T Cell Immunotherapy

Dr. Harbottle discusses how nS/MARt DNA vectors can provide robust transgene expression in every cell and model system available.

Popular Resources

Application Note
MaxCyte® Enables a cGMP-Compatible Manufacturing Process for Highly Efficient T Cell Engineering.
MaxCyte Flow Electroporation® Technology: A Safe, Reliable and Effective Method for Engineering CAR T Cells.
Application Note
CRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer.
View All Resources


The GTx is supported by an FDA Master File and has 21 CFR Part 11-enabled software. The GTx enables a closed cGMP-compliant process and is ISO-certified and CE-marked.

The GTx can rapidly transfect from 75 thousand to 20 billion cells.

The GTx has been used for advanced genome editing and clinical-scale engineering of adoptive cell therapies.

Still have questions?